Actuate Therapeutics Inc
ACTU
Rank in Stocks
#29636
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the... Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Share Price
$0.3022
Last synced: 2026-11-11
Market Cap
$7.21M
Change (1 day)
1.75%
Change (1 year)
-95.20%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Actuate Therapeutics Inc (ACTU)
Category
Healthcare
EPS for Actuate Therapeutics Inc (ACTU)
EPS as of June 2026 TTM: $-0.89
According to Actuate Therapeutics Inc's latest financial reports, its current EPS (TTM) is $-0.89. At the end of 2025 the company had an EPS of $-1.06, an increase over its 2024 EPS of $-3.26.
EPS history for Actuate Therapeutics Inc from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.89 | -16.04% |
| 2025 | $-1.06 | -67.48% |
| 2024 | $-3.26 | 97.58% |
| 2023 | $-1.65 | 23.13% |
| 2022 | $-1.34 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,859.55% |
US
|
|
| $-7.07 | 694.38% |
US
|
|
| $-5.29 | 494.38% |
AU
|
|
| $12.88 | -1,547.20% |
BE
|
|
| $21.56 | -2,522.47% |
NL
|
Questions about Actuate Therapeutics Inc's earnings per share (EPS)
What is Actuate Therapeutics Inc's earnings per share (EPS)?
Actuate Therapeutics Inc's earnings per share (EPS) over the last twelve months is $-0.89, as of Jun 2026.
What was Actuate Therapeutics Inc's earnings per share (EPS) in 2025?
In 2025, Actuate Therapeutics Inc's earnings per share (EPS) was $-1.06, compared with $-3.26 in 2024.
How has Actuate Therapeutics Inc's earnings per share (EPS) changed since 2022?
From 2022 to 2025, Actuate Therapeutics Inc's earnings per share (EPS) was highest in 2025 ($-1.06) and lowest in 2024 ($-3.26).
How does Actuate Therapeutics Inc's earnings per share (EPS) compare with similar companies?
Actuate Therapeutics Inc's earnings per share (EPS) ($-0.89) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.